Why This Genomics ETF Is a Long-Term Winner
September 15, 2020 at 13:57 PM EDT
The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) turns six years old next month and over that time, it’s developed a reputation as one of the best-performing healthcare ETFs, biotechnology or otherwise. That success is attributable to the ability of ARK Invest’s managers to...